Pasithea Therapeutics Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pasithea Therapeutics Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $486.6K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $15.1K | Mar 30, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | ($2.2K) | Mar 30, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.43M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($13.90M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($15.96M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($13.94M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($2.17M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($41.0K) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.86M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($14.25M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($15.98M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($12.59M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($4.51M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($41.0K) | Mar 30, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.98M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $7.20M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $8.10M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $2.67M | Mar 29, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.05M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $7.88M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $9.92M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.51M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $41.0K | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.21M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($13.92M) | Mar 30, 2026 |
| FY2022 | Dec 31, 2022 | ($14.56M) | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | ($3.17M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($38.7K) | Mar 30, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $34.3K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $107.1K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $21.5K | Mar 30, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.24M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $16.06M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $26.12M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $45.18M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $53.32M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $248.0K | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.02M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.28M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $2.72M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $2.68M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.90M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.6K | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.22M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $14.78M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $23.40M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $42.50M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $51.42M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $241.4K | Mar 30, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $1.26M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.26M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.26M | Mar 29, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($70.01M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($49.58M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($35.32M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($19.36M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($2.21M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($41.0K) | Mar 30, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.16M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.92M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $16.33M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $33.09M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $52.97M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $243.7K | Mar 30, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (12) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (12) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23.09M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 1.39M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 1.04M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 1.30M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 23.01M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 7.47M | Mar 30, 2022 |